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ARYL hydrocarbon hydroxylase (AHH)
is an enzyme system found in many tissues
and organs within the human body, as well
as in various mammalian cells, and which
is involved in metabolism of poly-
nuclear aromatic hydrocarbons (PAHs) to
more polar derivatives (Heidelberger,
1975). In the case of the metabolism of
PAHs such as benzo(a)pyrene (BP) it is
thought that one or moreofthe metabolites
is (are) the actual carcinogen(s) (Sims and
Grover, 1974; Gelboin et al., 1976;
Weinstein et al., 1976; Marquardt, 1977).
Using the originally proposed method of
Wattenberg et al. (1968), Nebert and
Gelboin (1968) developed a fluorimetric
assay for AHH activity, using liver micro-
somes for converting BP into 3-hydroxy-
benzo(o)pyrene (3-BPOH). Several reports
have shown that AHH, a mixed-function
oxidase, is induced in various tissues by
PAHs, drugs, steroids, insecticides and
other compounds (Conney, 1967; Nebert
and Gelboin, 1968; Gielen and Nebert,
1971, 1972; Luetal., 1972). Variousauthors
have demonstrated AHH activity in
human lymphocytes (Whitlock et al.,
1972; Busbee et al., 1972; Kellermannetal.,
1973a, b and c; Bast et al., 1976) and have
used BP with cultured lymphocytes to de-
termine the AHH activity by fluorimetric
measurement of the amount of 3-BPOH
formed. The fluorimetric method for AHH
activity in humanlymphocytes has created
much interest as a relatively simple screen-
ing test for susceptibility to bronchogenic
cancer (Kellermann etal., 1973b, c and d) as
caused by either cigarette smoking or
various other chemical agents (Alfred and
Bowens, 1975). Nevertheless, the test does
not appear very reproducible either in a
single laboratory or between laboratories
(Paigen et al., 1977; Cantelli Forti et al.,
1977). Hence, many variants ofthe original
fluorimetric method of Wattenberg et al.
(1968) and Nebert and Gelboin (1968) have
been published by different workers in an
attempt to improve its reproducibility and
accuracy (Whitlock et al., 1972; Busbee et
al., 1972; Kellermann et al., 1973a, band c;
Dehnen et al., 1973; Gurtoo et al., 1975;
Cantrell et al., 1976; Bast et al., 1976;
Paigen et al., 1977). It is the purpose of
this communication to examinesomeofthe
problems inherent in the fluorimetric assay
of AHH in human lymphocytes.
Six simulated experiments were per-
formed in test tubes, precisely according
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to the procedure developed by Kellermann
et al. (1973a, and b) for determination of
AHHactivitybythefluorimetricprocedure,
except for the fact that lymphocytes were
omitted from the test tubes. Each test
tube contained 0 9 ml of a buffer mixture
(TMS, see Busbee et al., 1972) consisting of
TRIS (final concentration 50 mM), MgCl2
(final concentration of 3 mM) and sucrose
(final concentration 200 mM). In addition
there was added 0 70 mg NADH+0-70 mg
NADPH in a volume of 0-10 ml of TMS.
The freshly prepared mixture was incu-
bated immediately after the addition of
unlabelled BP (25 Hg) mixed with 25 x
10-3 tCi oflabelled BP in 50 pi ofacetone.
The unlabelled BP (980% pure, m.p.
175-177°C, Aldrich Chemical Co.) and the
generally tritiated benzo(o)pyrene ([G-3H]
BP) (Amersham/Searle Co; sp. act. 5 Ci/
mmol; 20 mCi/mg; radioactive concentra-
tion, 5 mCi//ml in benzene; BP concentra-
tion, 0-250 mg/ml) were purified by thin-
layer chromatography 2-dimensionally on
silica gel G (Merck pre-coated plates) using
first, benzene and then 1:15 (v/v) benzene:
hexane. The major, 0 90 Rf, fraction was
retained and an acetone stock solution was
prepared for the experiments.
Incubation of the test tubes was carried
out in a shaking bath at 37+0 050C for
30 min. At the end of this time, 4 ml of
25% acetone in hexane was added. The
tubes were mixed on a vortex for 1 min
and the phases separated by centrifuga-
tion at 400 g for 3 min.
The buffered aqueous phase (A) was
recovered and transferred directly into a
liquid-scintillation vial containing 10 ml
of PCSTM cocktail (Phase Combining
SystemTRADE MARKAmersham/Searle Co.).
The organic phase was vortexed in another
test tube with 1 ml of IN NaOH. After
additional mixing for 1 min and centrifu-
gation, the phases were separated. The
organic phase (B) and the NaOH phase (C)
were each transferred into 10 ml of PCSTM
cocktail in liquid-scintillation vials.
Standards of buffer mixture, hexane:
acetone (1: 3 v/v) mixture, IN NaOH and
BP solution (unlabelled) were added
separately to 10 ml of PCSTM cocktail, to
obtain the quenching calibration curves.
A Beckman model LS-100 was used for
radioactive measurements.
All experiments were made using yellow
light, because of the observed and widely
known photo-decomposition of BP and its
metabolites. Fluorescence spectra were
obtained on a Perkin-Elmer Model MPF-
2A, using an excitation wavelength of
396 nm.
TABLE I.-Percent recovered radioactivity in
variousphases using [G-3H]BP in Keller-
mannet al. (1973a, b)procedureforfluori-
metric assay
00 of total activity
foundl in the TMS
buffer phase (A)
0 of total activity
found in the organic
phase (B)
00 of total activity
foundl in the 1N-
NaOH phase (C)
0 Total recovere(I
activity
AMean
±s.e.
n=6
0*29+006
86 88X1*1-85
11*72±0 82
Confidence
limits
(P<0 05)
0-12
0 45
82-11
91 *65
9-61
13 -82
98*89+-242 92-72
105-06
Table I shows the percentage of total
radioactivity found in the various phases,
using the procedure of Kellermann et al.
(1973a, andb) intheabsence ofhumanlym-
phocytes but with [G-3H]BP. The most
significant fact is that 11.72% of the total
radioactivity ends up in the NaOH phase
(C), while the method was developed to
ensure that no BP, only 3-BPOH, was
being extracted by the NaOH. It should be
noted that the total recovery of radio-
activity is 98 89%, suggesting minimal
error due to losses.
On the basis of the data in Table I,
fluorimetric scans were made on various
concentrations of 3-BPOH in IN NaOH.
For each concentration, a scan was made
in the absence and presence of 6 pA of BP
solution (0 50,ug/uld) added to each solu-
tion after measuring the 3-BPOH alone.
This amount of added BP represents 110%
of the total amount of BP added to the
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TABLE II. Fluorimetric measurements on 3-BPOH and (3-BPOH+BP)
concentrations of 3-BPOH*
for different
Slits: emission 5
excitatioI 5)
3-BPOH
concentration
(m)
10 -5
10 -6
10 -7
10 -8
10 -9
Fluorescence
3-BPOH 3-BPOH+-6,ul of 0 5
only ,ug'ltl BP solution
240
20
4
2
310
128
70
55
35
Slits: emission 10,
excitation 10 10-9 95 195 2-05
10-1( 43 168 3-91
10 -11 28 120 4 29
10 -12 14 84 6-00
* Perkin-Elmer fluorescance spectrophotometer Model MPF-2A; excitation 396 nm; emission 522 nm;
sensitivity 4. Values were obtained from recorded scans using a fixed excitation at 396nm.
t Arbitarary units.
lymphocytes in the modified fluorimetric
procedure ofKellermann et al. (1973a,andb)
close to that percentage found in Phase C
(Table I). The results of the study are
summarized in Table II. It is clear that at
high concentrations of 3-BPOH (<10-5M)
there is not much difference between the
fluorescence values. However, as the con-
centrations of 3-BPOH decrease, a sub-
stantial positive error occurs, as shown by
the increasing ratio. Data in Table I also
show the effect of slit width. At 10-9M
3-BPOH, slits of 5 give a ratio of 35, while
slits of 10 lead to a ratio of 2. Depending on
the slit width and concentration, the ratio
of fluorescence intensity of the solution
with BP to that without BP may be as
large as 35:1 or as small as 1P3:1. Clearly,
the larger the slit widths for excitation and
emission, the smaller the ratio, although a
larger slit width decreases the slope of the
log fluorescence vs-log concentration curve
(not shown).
The implications of these results are: (1)
that 11 7%o ofthe BP is extracted bythe
NaOH in the fluorimetric method, (2) that
its fluorescence spectrum has one peak
with a wavelength maximum at 522 nm,
the same as for 3-BPOH; hence there is a
substantial interference of the BP in the
measurement of the fluorescence intensity
of 3-BPOH, (3) as the concentration of
23
3-PBOH decreases and the slit width
decreases, this effect becomes more
substantial.
Inducibility as noted by Kellermann et
al. (1973b and c) is measured bycomparing
thefluorescenceintensity at 522 nm(excita-
tion at 396 nm) with 3-methylcholanthrene
(3-MC) incubation to that without 3-MC
addition. This ratio x 100 is the percent
inducibility. Assuming no actual induci-
bility, if the amount of BP extracted from
the split lymphocyte sample (induced and
uninduced) varies, there will be either an
apparent positive induction or negative
induction, depending upon which half
extracts the greater amount of BP. Thus,
the apparent inducibility as measured by
fluorescence may be a complete artifact,
due to unequal BP contamination in the
"induced" and "uninduced" samples.
This point is emphasized by our results
using the conventional fluorimetric pro-
cedure modified by Kellerman et al.
(1973a and b) for AHH assay on human
lymphocytes. Out of 68 samples, 24 showed
a negative induction. The observed nega-
tive induction may be in part due to an
artifact in the procedure, as noted, result-
ing from fluorimetric interference ofBP. It
also may be a true effect resulting from the
interaction of various individual genetic
and environmental factors (Cantelli Forti
Ratio
1*29
6 40
12 50
27 *50
35 00
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et al., 1977). Also, although we have notyet
quantitated this, other metabolites present
may interfere, as shown by Holder et al.
(1975). Data onthe presence ofother meta-
bolites as detected by radioisotopic assay
developed by uswillbepresentedelsewhere
(Cantelli Forti et al., 1977).
In summary, the fluorimetric procedure
such as that of Kellermann et al. (1973a
andb) forAHH inducibility in human lym-
phocytes has a number of inherent prob-
lems. These are: (1) the extraction of BP
along with 3-BPOH, and probably other
metabolites, and their fluorimetric interfe-
rence, (2) the photochemical instability of
the BP, 3-BPOH and other metabolites
which may lead to additional errors if
proper precautions are not taken. This
paper emphasizes the first point.
We are grateful for the generous support of this
work by Dow Chemical Co., U.S.A. We also wish to
acknowledge the kind gift of 3-hydroxybenzo[a]-
pyrene by Dr Harry V. Gelboin, N.C.I., Bethesda,
MD, USA.
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